Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
Several technologies for hemoglobinopathies are being transferred to commercial partners
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
Athena is also exploring the use of this technology for expanded carrier screening
cSCC is one of the most common cancers in the U.S. and globally
This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
Subscribe To Our Newsletter & Stay Updated
